Leonid Reshko, MD
Radiation Oncology · Newport News, VANPI 1770016065
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,557 of the $2,508 with a category attached, or 62.1%. 21 manufacturers reported payments, led by Elekta, Inc. at 37.9% of the total. Reporting peaked in 2024 at $1,303 and has fallen 98.1% since, to $25 in 2025.
Across 57 payments — averaging $44.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Elekta, Inc.$951
- AstraZeneca$285
- Novocure Inc.$236
- Boston Scientific$167
- Progenics Pharmaceuticals, Inc.$160
- Bristol Myers Squibb$129
- plus $579 from 15 others
What the payments were for
- Travel & lodging$95138%
- Food & beverage$1,55762%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Elekta, Inc. | 2 | $951 |
| AstraZeneca | 4 | $285 |
| Novocure Inc. | 6 | $236 |
| Boston Scientific | 3 | $167 |
| Progenics Pharmaceuticals, Inc. | 3 | $160 |
| Bristol Myers Squibb | 11 | $129 |
| Tactile Systems Technology Inc | 1 | $118 |
| Merck | 6 | $94 |
| Reflexion Medical, Inc. | 3 | $74 |
| Tesaro, Inc. | 4 | $53 |
| Incyte Corporation | 4 | $48 |
| Zap Surgical Systems, Inc. | 1 | $38 |
| Arbor Pharmaceuticals, Inc. | 1 | $26 |
| Siemens Medical Solutions USA, Inc. | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Blue Earth Diagnostics | 1 | $17 |
| Eisai Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Amgen | 1 | $14 |
| Sanofi | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMFINZI$125
- GENERAL ONCOLOGY$123
- TAGRISSO$120
- Flexitouch Plus$118
- Entre Plus$118
- NovoTTF-100L$115
- PYLARIFY$115
How this compares
$2,508 in reported general payments places this provider in the 80th percentile of 121 radiation oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mometasone Furoate | 59 | $1,270 |
| Lidocaine Hcl ViscousLidocaine Hcl | 13 | $299 |
| Dexamethasone | 16 | $277 |
| Tamsulosin Hcl | 27 | $155 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Newport News
- E Ronald HaleNewport News$501
- Daniel KimFairfax$406K
- Samir KananiFairfax$90K
- David PenberthyCharlottesville$67K
- Gopal BajajFairfax$23K
- Ashish ChawlaFairfax$14K
- David BuckRoanoke$13K
- Kara RomanoCharlottesville$11K
- Gregory SibleyFairfax$10K
- Anthony CrimaldiCulpeper$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.